We propose that the lower incidence of tislelizumab-associated RP, compared with other PD-1 inhibitors, may be attributed to its FcγR binding affinity, target engagement profile, and divergent immune effector functions (28). This evidence concerns the gene FCGR2A and retinitis pigmentosa 1.